Astegolimab
- Generic Name
- Astegolimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2173054-79-8
- Unique Ingredient Identifier
- 27TW751DTH
- Background
Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
- Associated Conditions
- -
- Associated Therapies
- -
Regeneron and Sanofi's Dupixent Tipped to Dominate COPD Biologics Market
Regeneron and Sanofi won FDA approval for Dupixent in COPD, targeting 300,000 U.S. adults with eosinophilic phenotype. GlobalData forecasts $6.57 billion in 2033 sales, while Sanofi and BMO Capital Markets predict $5.5 billion and $2.5 billion respectively. Competitors AstraZeneca, GSK, and Roche have ongoing trials for their biologics in COPD. Regeneron and Sanofi aim to establish market presence before rivals launch.
4 things pulmonologists are excited about for the future of COPD care
COPD treatment advances include precision medicine, biologics like dupilumab, biomarkers for early diagnosis, remote monitoring, omics tech, and regenerative medicine, promising more personalized and effective care.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath